Drugs / Quadrivalent influenza vaccine
Quadrivalent influenza vaccine
Trials 54 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05585632 | Oct 2022 → Feb 2024 | Orthocoronavirinae infectious disease, influenza, respiratory syncytial virus infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05397223 | May 2022 → Feb 2026 | COVID-19, cytomegalovirus infection, influenza, respiratory syncytial virus infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02988739 | Feb → Jul 2017 | influenza | Pantec Biosolutions AG | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05375838 | May → Dec 2022 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04956575 | Jul 2021 → Sep 2022 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT05868382 | May → Dec 2023 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05606965 | Nov 2022 → Nov 2025 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04363359 | Jan 2020 → Sep 2021 | influenza | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 2 | NCT03336593 | Nov 2017 → Mar 2018 | — | PT Bio Farma | Completed | No outcome recorded |
| Phase 2 | NCT01344057 | May → Jun 2011 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT01357265 | May 2011 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT01152814 | Jun 2010 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT01123954 | Jan → Mar 2010 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00956449 | Jun → Jul 2009 | influenza | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00734734 | Jun → Jul 2008 | — | Novartis Vaccines | Completed | No outcome recorded |
| Phase 323 trials | ||||||
| Phase 3 | NCT06602024 | Sep 2024 → Aug 2025 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06049927 | Sep 2023 → May 2024 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05827978 | Apr 2023 → Jun 2024 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05566639 | Sep 2022 → Jan 2024 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05245552 | Aug 2022 → Aug 2023 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05415462 | Jun 2022 → Sep 2023 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05028634 | Nov 2021 → Nov 2023 | relapsing-remitting multiple sclerosis | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04848467 | Oct → Nov 2021 | COVID-19 | Bayer | Withdrawn | No outcome recorded |
| Phase 3 | NCT04544267 | Sep 2020 → Jun 2021 | influenza | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
| Phase 3 | NCT04210349 | Jan → Dec 2020 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04001504 | Jul 2019 → Aug 2022 | acute coronary syndrome | Hospital Israelita Albert Einstein | Completed | No outcome recorded |
| Phase 3 | NCT03765437 | Jan → Mar 2019 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03744104 | Oct 2018 → Oct 2019 | influenza | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 3 | NCT03859141 | Feb → Apr 2018 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03853993 | Jan → Aug 2018 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02710409 | Jan → Jun 2016 | influenza | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT01967784 | Oct 2013 → Apr 2014 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01687517 | Oct 2012 → Jun 2013 | sarcoidosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01481454 | Mar → Oct 2012 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01422512 | Sep → Oct 2011 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01240746 | Nov 2010 → Dec 2011 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01063088 | Feb → Mar 2010 | influenza | Alachua Government Services, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00735410 | Jun → Jul 2008 | — | Novartis Vaccines | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT05970887 | Oct → Dec 2022 | — | Catholic Kwandong University | Completed | No outcome recorded |
| Phase 4 | NCT05996549 | Sep 2022 → Jul 2024 | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
| Phase 4 | NCT05471531 | Nov 2021 → Mar 2022 | — | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT05499351 | Oct → Dec 2021 | COVID-19 | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT04997239 | Oct 2021 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT05108818 | Oct 2021 → Apr 2027 expected | influenza | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 4 | NCT05313893 | Sep → Dec 2021 | influenza | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT04801888 | Mar → May 2021 | COVID-19, influenza | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04667117 | Jan 2021 → Jul 2023 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02915302 | Sep 2016 → Mar 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT02748785 | Sep 2015 → Aug 2016 | rheumatoid arthritis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03546192 | Jun → Jul 2015 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT02105519 | Oct 2013 → Jun 2014 | chronic kidney disease | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT01906190 | Aug 2011 → Mar 2013 | influenza | Centers for Disease Control and Prevention, China | Completed | No outcome recorded |
| — | NCT01202552 | Oct 2010 → Apr 2018 | influenza | Queen Saovabha Memorial Institute | Completed | No outcome recorded |
| — | NCT01651754 | Sep 2010 → Aug 2011 | myalgic encephalomeyelitis/chronic fatigue syndrome | Radboud University Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 17 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05227001 Comparator | Apr 2022 → Aug 2023 | influenza | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01444482 Comparator | May → Nov 2011 | influenza | Isconova AB | Unknown | No outcome recorded |
| Phase 1 | NCT01405885 Comparator | May 2011 → Aug 2013 | — | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00798343 Comparator | Jan 2009 → Mar 2010 | influenza | University Hospitals, Leicester | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05827068 Comparator | Mar → Nov 2023 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT05333289 Comparator | Apr → Nov 2022 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03300362 Background | Oct 2017 → Oct 2018 | influenza | Barinthus Biotherapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT02860039 Comparator | Sep 2016 → Dec 2021 | cancer, disease related to hematopoietic stem cell transplant, influenza | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00620815 Comparator | Nov 2007 → Jan 2008 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT05513391 Comparator | Nov 2022 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
| Phase 3 | NCT05540522 Comparator | Sep 2022 → Mar 2024 | influenza | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01964989 Comparator | Nov 2013 → Oct 2015 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 3 | NCT01199861 Background | Aug 2010 → May 2011 | multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01040078 Comparator | Dec 2009 → Feb 2010 | swine influenza | Centers for Disease Control and Prevention, China | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01980836 Comparator | Nov 2013 → Feb 2014 | rheumatoid arthritis | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06827873 Background | Feb → May 2025 overdue | — | Tsinghua University | Not yet recruiting | No outcome recorded |
| — | NCT02765126 Comparator | May 2016 → Dec 2019 | — | Clifford Craig Medical Research Trust | Unknown | No outcome recorded |
Press releases naming this drug 11 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-17 | CSL Behring | CSL Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025 csl.com ↗ |
| 2021-12-07 | CSL Behring | New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults csl.com ↗ |
| 2021-10-14 | CSL Behring | The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to < 18 Years of Age csl.com ↗ |
| 2021-09-29 | Pfizer | Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released pfizer.com ↗ |
| 2020-12-14 | CSL Behring | Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020 csl.com ↗ |
| 2020-12-14 | CSL Behring | Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Value of MF59®-Adjuvanted Seasonal Influenza Vaccine csl.com ↗ |
| 2020-06-08 | CSL Behring | First adjuvanted quadrivalent influenza vaccine receives EU approval csl.com ↗ |
| 2020-03-31 | CSL Behring | Seqirus announces positive CHMP Opinion for its adjuvanted quadrivalent influenza vaccine csl.com ↗ |
| 2019-12-11 | CSL Behring | Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine csl.com ↗ |
| 2019-12-09 | CSL Behring | New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine csl.com ↗ |
| 2019-01-14 | CSL Behring | First cell-based quadrivalent influenza vaccine approved for use in Europe csl.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 75 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | quadrivalent influenza vaccine | “the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.” NCT05499351 ↗28 |
| Known as | FLUAD | “A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza...” NCT00734734 ↗ |
| Known as | Fluzone Quadrivalent Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03546192 ↗ |
| Known as | Fluzone Quadrivalent vaccine, No Preservative | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02915302 ↗ |
| Known as | IIV4 | “Inactivated quadrivalent influenza vaccine (IIV4) containing two influenza A strains and one strain from each B lineage (Yamagata and Victoria) may offer broader protection...” PMID 25843270 ↗ Apr 20153“Inactivated quadrivalent influenza vaccine (IIV4) containing two influenza A strains (H1N1 and H3N2) and one strain from each B lineage (Victoria and Yamagata)” PMID 32732142 ↗ Jul 2020 “non-adjuvanted inactivated influenza vaccine (ie, trivalent inactivated influenza vaccine [IIV3] or quadrivalent inactivated influenza vaccine [IIV4])” PMID 29631857 ↗ Apr 2018 “Biological: Quadrivalent influenza vaccine (IIV4)” NCT05513391 ↗ |
| Known as | mRNA-1010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05868382 ↗ |
| Known as | mRNA-1010.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05827068 ↗ |
| Known as | mRNA-1010.3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05827068 ↗ |
| Known as | QIV | “The aim of the study is to assess the safety profile of a quadrivalent influenza vaccine (QIV) and to demonstrate that 3 different industrial lots of QIV induce an equivalent...” NCT01481454 ↗5“Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)” NCT01964989 ↗ “new formulation of Quadrivalent Influenza Vaccine (QIV) for the 2013-2014 season” NCT01967784 ↗ “flu vaccine called seasonal quadrivalent influenza vaccine (QIV)” NCT04848467 ↗ “licensed quadrivalent influenza vaccine (QIV)” NCT05540522 ↗ “Quadrivalent influenza vaccine (QIV)” NCT05227001 ↗ |
| Known as | QIV-HD | “high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD)” NCT04544267 ↗ |
| Known as | QIV-SD | “high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD)” NCT04544267 ↗ |
| Known as | SD-QIV | “We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given 4 weeks apart were more...” PMID 39279435 ↗ Feb 2025 |
| Known as | Seasonal flu vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01152814 ↗ |
| Known as | Seasonal influenza vaccination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01651754 ↗ |
| Known as | seasonal influenza vaccine | “Non-adjuvanted seasonal influenza vaccine (total dose 45ug)” NCT00798343 ↗23 |
| Known as | Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06827873 ↗ |
| Known as | standard-dose quadrivalent influenza vaccine | “We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given 4 weeks apart were more...” PMID 39279435 ↗ Feb 2025 |
| Modality | Vaccine | “seasonal influenza vaccine” NCT00620815 ↗ |
| Route | Intramuscular | “1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation” NCT00734734 ↗ |